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Abstract. Background/Aim: Salvage radiotherapy improves
biochemical control in patients with recurrence of prostate
cancer after prostatectomy. Radiotherapy target volumes of
the prostatic fossa are based on empirical data and differ
between different guidelines. Localization of recurrence with
multiparametric magnetic resonance imaging (MRI) might
be a feasible approach to localize recurrent lesions. Patients
and Methods: Twenty-one patients with biochemical
recurrence after radical prostatectomy were included
(median prostate-specific antigen (PSA) =0.17 ng/ml). Multi-
parametric MRI was performed using a 3-T MR system.
Results: Lesions were detected in seven patients with a
median PSA of 0.86 ng/ml (minimum= 0.31 ng/ml). Patients
without detectable recurrence had a median PSA of 
0.12 ng/ml. All patients with detectable lesions responded to
radiotherapy. Eleven out of 14 patients without detectable
recurrence also responded. Plasma flow in suspicious lesions
was correlated with PSA level. Conclusion: Detection of
recurrence at the prostatic fossa with our approach was
possible in a minority of patients with a low PSA level.
Clinical relevance of plasma flow in suspicious lesions
should be further investigated. 
Prostate carcinoma is the second most common cancer in males
(1) and although mortality rates have decreased in European
countries and the United States (US), it still accounts for more
than 258,000 deaths worldwide (2). According to the US-
population-based Surveillance, Epidemiology, and End Results
Program database, ~80% of men with newly diagnosed
prostate carcinoma had localized disease at the time of
diagnosis (3). Most of these patients selected radical
prostatectomy or external beam radiotherapy as their primary
treatment option (4, 5). Recurrence rates after radical
prostatectomy differ widely between around 10% of patients
and more than 30% within 5 years (6-8), depending on Gleason
score and other risk factors (6). In patients with positive
surgical margins, it can be estimated that 20-40% of tumors
recur (9, 10) and the majority of patients with biochemical
relapse are diagnosed as having local recurrence (11).
Radiotherapy as salvage treatment has been shown to improve
biochemical control in patients with residual disease or
biochemical relapse (12, 13). Stephenson et al. estimated that
biochemical control can be achieved by radiotherapy in 48%
of patients when salvage treatment starts before the prostate-
specific antigen (PSA) level reaches 0.5 ng/ml; if administered
at a PSA level of 0.5 ng/ml and above, only 26% of patients
treated were free from (further) relapse (14). These results have
been confirmed by modern series which additionally showed a
clinical benefit in terms of distant metastasis-free survival,
disease-specific mortality, and all-cause mortality (15).
Furthermore, modern series indicated early salvage
radiotherapy, initiated at the earliest sign of measurable PSA,
to be beneficial in terms of biochemical and clinical endpoints
(15, 16). Severe toxicity of salvage radiotherapy is generally
reported to be low (17) but even in modern series, there is a
residual risk of grade 3/4 bowel or urinary toxicity (18). 
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Timing of salvage treatment in patients who have not
received adjuvant radiotherapy remains controversial.
According to National Comprehensive Cancer Network
(NCCN) guidelines (19) “treatment is most effective when
pre-treatment PSA level is below 0.5 ng/ml”; however, the
indication for salvage radiotherapy also includes “an
undetectable PSA that becomes detectable and then increases
on 2 subsequent measurements” (19). European guidelines
propose salvage radiation before the PSA level increases to
0.5 ng/ml (20), and the American Society for Radiation
Oncology/American Urological Association guidelines at
earliest sign of PSA recurrence after undetectable PSA has
been achieved (17). The latter approach is in line with
aforementioned studies by Stish et al. (15), as well as that of
Tendulkar et al. (16), published in 2016. 
Local relapses are located at the urethro-vesical
anastomosis in most cases (21-23). There are, however
considerable differences in target volume definition between
the four published consensus guidelines of the European
Organisation for Research and Treatment of Cancer (24), the
Radiation Therapy Oncology Group (25), the Australian and
New Zealand Radiation Oncology Genito-Urinary Group
(26), and the Princess Margaret Hospital (27)] in terms of
size and prostate bed coverage (28, 29). In a comparative
study (29), radiotherapy plans contoured according to
consensus guidelines failed to meet QUANTEC (30), and
RADICALS (31) trial dose constraints in 75%, and 40% of
cases, respectively. These inconsistencies indicate that our
current approaches to salvage treatment of prostate
carcinoma after radical prostatectomy should be reassessed.
Improvement of therapeutic efficacy could be achieved by
reducing geographical miss and side-effects by accurate
detection of residual disease.
Detection of residual prostate carcinoma is possible by
magnetic resonance imaging (MRI) and positron-emission
tomography–computed tomography (PET-CT). Evidence on
restaging of biochemically relapsed patients with PET-CT was
recently reviewed by Umbehr et al. (32). The authors analyzed
12 studies and found a pooled sensitivity and specificity of
85%, and 88%, respectively (mean PSA=7.9 ng/ml). In patients
with early relapse (PSA <1 ng/ml), however, the authors found
no convincing evidence for the use of PET-CT. 
MRI with (33-35) and without (36) endorectal coil
represents an alternative for detecting local recurrence after
radical prostatectomy. Most studies have been performed on
1.5-T MR systems (33-36) and local recurrence was in some
cases detected in patients with PSA levels of 1-2 ng/ml or
less (35-38). Despite these results, it remains controversial,
if local recurrence may be detected by 1.5-T MRI before
PSA levels rise above 1 ng/ml (20). This would facilitate
early targeted salvage radiation before a PSA level is
reached of which probability for biochemical control is
impaired (14, 39).
We assumed that with 3-T MRI protocols (40-42), detection
of local recurrence after radical prostatectomy is feasible at
early stages when the PSA value is still below 1 ng/ml.
Accurate detection would further reduce geographical miss
and most probably enhance therapeutic ratio, by dose
escalation to small residual volumes (18) or reduction of
treated volumes. In addition, visualization of tumor
vasculature with quantification of plasma flow (PF) and mean
transit time (MTT) might further add functional information
for improved target definition.
Patients and Methods
Patients. From September 2008 to November 2012, 28 patients with
suspected local recurrence after radical prostatectomy were scanned
by MRI. Seven patients were excluded from analysis because of
identification of metastatic disease at MRI in two, refusal of
radiotherapy in one, missing PSA test between surgery and
radiotherapy in one, technical problems in one and artifacts due to
foreign material in the bladder, and MRI appointment after start of
radiotherapy in two. The majority of the remaining 21 patients
presented because of PSA persistence or progression after R0
surgery in 14, biochemical progression after R1 surgery in five, and
R1 surgery with residual PSA level in two.
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Table I. Characteristics of 21 patients after radical prostatectomy for
prostate carcinoma.
Characteristic                                                                Value
Gleason score, n
   6                                                                                     1
   7                                                                                    14
   8                                                                                     3
   9                                                                                     3
T-Stage, n
   pT2                                                                                11
   pT3                                                                                10
N-Stage, n
   N0/pN0                                                                         18
   pN1                                                                                2
   pNx                                                                                1
M-Stage, n
   M0                                                                                 21
Resection status, n
   R0                                                                                  11
   R1                                                                                   8
   R2                                                                                   1
   Rx                                                                                   1
Age, years
   Min-Max                                                                    49-75
   Median                                                                          64
PSA at time of MRI, ng/ml
   Min-Max                                                                  0.03-4.3
   Median                                                                        0.17 
MRI, Magnetic resonance imaging; PSA, prostate-specific antigen.
All patients included in the analysis received radiotherapy to the
prostatic fossa. Target volume dose was 70 Gy (five fractions per week,
2 Gy per fraction); patients with identifiable localization of residual
disease (either by MRI or by positive surgical margins) received an
integrated boost up to 75 Gy targeted at the recurrent tumor volume.
Irradiation of pelvic lymph nodes was performed to a dose of 44 Gy if
positive nodes were found at surgery or if lymph node resection was
deemed insufficient, and the preoperative risk of lymph node
involvement was >15% based on the Roach-Formula. Detailed results
of the radiotherapy regimens applied have been reported elsewhere
(18). Further patient characteristics are detailed in Table I. This
retrospective study was approved by the Ethics Committee of
Heidelberg University, Medical Faculty Mannheim (2008-338N-MA).
MRI protocol. MRI was performed on a 3-T MR system (Magnetom
TimTrio; Siemens Healthineers, Erlangen, Germany) utilizing a 12-
channel body coil. To suppress bowel motion, up to 40 mg N-
butylscopolaminium (Buscopan®; Boehringer Ingelheim GmbH,
Ingelheim, Germany) was injected intravenously. All patients were
examined in feet-first supine position. Imaging protocols consisted
of a high-resolution, T2-weighted triplanar turbo spin echo
sequence, an axial, fat-suppressed, single-shot, echo-planar
diffusion-weighted imaging (DWI) sequence and an axial, 2D, T1-
weighted dynamic contrast-enhanced DCE scan using a spoiled
gradient echo saturation recovery TurboFLASH sequence. The DCE
MRI examination was performed after bolus injection of 0.1
mmol/kg body weight of gadolinium chelate (Dotarem®; Guerbet,
Roissy, France) with a bolus velocity of 2.5 ml/s using a power
injector (Medrad Inc., Pittsburgh, PA, USA) followed by a saline
flush of 40 ml. Imaging parameters of the T2w, DCE and DWI
sequence MRI are summarized in detail in Table II. 
Post-processing and data analysis.A radiologist (M.S.) with 5 years’
experience in prostate MRI post-processed the DCE MRI data using
open source software tool towards quantitative MRI perfusion
analysis (UMM Perfusion, OsiriX DICOM viewer, Version 3.9.4; The
OsiriX Foundation, Geneva, Switzerland) (43). For each patient,
nodules with focally altered perfusion parameters in the prostate bed
were considered suspicious. DCE and T2-weighted images were also
taken into account for differential diagnosis between nodules and
artifacts such as clips or bowel movements. Contrast enhancement
curves were analyzed with a model-free deconvolution analysis as
described elsewhere (40, 41, 44). The arterial input function was
measured in a plane with clear delineation of the common femoral
artery at arrival of contrast agent. Quantitative color-coded maps of
PF and MTT were calculated by de-convolving pixel-based
concentration-time curves with the AIF as published previously (40-
42). On the quantitative color-coded PF and MTT maps, nodular
lesions with increased PF and decreased MTT values in comparison
to the surrounding structures were defined as suspicious for
recurrence, and one region of interest (ROI) was drawn in the area
with suspicious increased PF and decreased MTT values in the
prostatic fossa. For all ROIs, PF and MTT values were measured as
the mean of pixel values. A defined ROI volume of 0.2×0.2 cm2 was
delineated for all detectable lesions. 
Statistical analysis. Statistical analysis was performed using SPSS
15.0 (SPSS Inc., Chicago, IL, USA). Significance was defined as
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Figure 1. Suspected local recurrence after radical prostatectomy in magnetic resonance imaging (MRI). Dynamic contrast-enhanced MRI
(quantitative color-coded maps) demonstrates nodular lesion with increased plasma flow (PF) (a) and decreased mean transit time (MTT) values
(b) in comparison to the surrounding tissue (PF=159.3 ml/100 ml/min; MTT=65.32 s).
Table II. Scan parameters of the T2-weighted, dynamic contrast-
enhanced (DCE) and diffusion-weighted imaging (DWI) magnetic
resonance imaging sequences.
Parameter                                  T2w                 DCE                  DWI
TR/TE (ms)                          4,000/101         3.85/1.42            4,900/88
Sequence type                           TSE               TWIST                 EPI
FOV (mm × mm)                  200×200          260×260            204×204
Matrix                                    320×320          160×160            136×136
Number of slices                   19/23/19               20                      20
Slice thickness (mm)                  3                     3.6                       3
Interslice gap (mm)                   0.3                     0                        0
Spatial resolution (mm3)   0.6×0.6×3.0     1.6×1.6×3.6       1.5×1.5×3.0
b Values (s/mm2)                         -                       -             0, 50, 500, 800
Flip angle (˚)                      137/150/150            12                        -
Parallel imaging factor       Grappa (2)       Grappa (2)         Grappa (2)
Temporal resolution (s)               -                    4.22                      -
Averages (n)                                4                       -                         8
Acquisition time (min)     4.26/4.1/3.38          5.02                    5.4
TSE, Turbo-spin-echo; TWIST, time-resolved angiography with
interleaved stochastic trajectories; EPI, single-shot echo-planar imaging;
TR, repetition time; TE, echo time; FOV, field of view. 
p≤0.05. Differences of quantitative variables between independent
groups were tested using the Mann-Whitney U-test. The two-sample
paired Wilcoxon test was used to compared quantitative variables
between corresponding samples (pre-therapeutic vs. post-
therapeutic). Correlations among continuous variables were
computed by Spearman’s rank-order correlation. 
Results
Two independent radiologists who were blinded to PSA
levels identified suspicious nodular lesions with increased PF
and decreased MTT values in seven out of 21 cases (an
example is depicted in Figure 1). 
The median PSA level in patients whose local recurrence
was identified in MRI was 0.86 ng/ml [mean=1.65 ng/ml;
standard deviation (SD)=1.67 ng/ml]). The minimum PSA
level in a patient whose tumor was suspected by MRI was
0.31 ng/ml. Of seven patients with suspicious findings in
MRI, five had a PSA level of less than 1 ng/ml (three of
these patients had a PSA level less than 0.5 ng/ml). 
In patients without detectable recurrence, the median PSA
was 0.12 ng/ml (mean=0.168 ng/ml; SD=0.174 ng/ml). Two
out of 14 patients whose recurrence was not detected by MRI
had a PSA value greater than 0.21 ng/ml (0.33 and 0.71
ng/ml, respectively; see Figure 2). The difference between
PSA levels in patients with suspected lesion in MRI versus
those without localizable tumor was significant (p=0.001;
Mann-Whitney U-test; Figure 2). 
In the group of patients with lesions deemed as suspicious
by MRI, PF at the suspect lesion (ROI=0.2×0.2 cm) was
associated with increased PSA level (p=0.014; r=0.857;
Spearman’s rank correlation coefficient), MTT was not
associated with PSA (p=0.383; r=−0.393) or PF (p=0.253;
r=−0.5) in the analyzed group of patients. 
In the first follow-up examination after radiotherapy (6-12
weeks after irradiation), the median PSA level was reduced as
compared to the pre-radiotherapy level in all patients whose
recurrent tumor had been detected by MRI (0.04 ng/ml after
radiotherapy vs. 0.86 ng/ml before radiotherapy; p=0.018;
Wilcoxon test). In patients whose tumors was not detected by
MRI, the median PSA level in the first follow-up after
radiotherapy was also lower as compared to the pre-therapeutic
level (0.085 ng/ml after radiotherapy vs. 0.12 ng/ml before
radiotherapy; p=0.039; Wilcoxon test). In two patients of the
group with undetectable recurrence, the PSA level after
radiotherapy had risen, and in one patient, PSA was unchanged
as compared to the level before radiotherapy, consistent with
suspected distant disease. 
Discussion
Optimal timing of salvage radiotherapy is still the subject of
discussion. Subanalyses of the SWOG8974 trial demonstrated
improved metastasis-free survival in patients with all PSA
levels (<0.2 ng/ml, 0.2-1.0 ng/ml, >1.0 ng/ml) after
prostatectomy when salvage radiotherapy was applied (11).
Nevertheless, accumulating evidence indicates that treatment
should be initiated early after the detection of biochemical
recurrence at a PSA level of 0.2 ng/ml. In a systematic review
encompassing 5597 patients, King estimated that each further
PSA increment of 0.1 ng/ml is associated with an average
2.6% loss of biochemical relapse-free survival (39). Given
these findings and the need to further improve the therapeutic
ratio in salvage radiotherapy, we should aim for early
detection of local recurrence by modern imaging techniques.
As discussed above, there is currently no convincing evidence
for the use of PET-CT in this clinical setting (32). 
In our series reported here, we were able to detect areas
highly suspicious for local recurrence at PSA values below 0.5
ng/ml at a minimum level of 0.31 ng/ml, indicating that some
tumors in patients with a PSA value of 0.2-0.5 ng/ml can be
detected by our method. We were not able to detect any local
recurrence in patients with a PSA level below 0.3 ng/ml and
we failed to identify local relapse in three patients with PSA
levels of 0.2 ng/ml and greater (0.209, 0.33, and 0.71 ng/ml),
although these patients responded to local therapy, indicating
that local relapse not visible by MRI was present. 
Recent literature on the topic shows that local recurrence was
detected in larger series at a PSA level of around 0.8-1.3 ng/ml
(45, 46). Cirillo and coworkers estimated sensitivity of 84% and
specificity of 89% in patients with a PSA level of ~1.2 ng/ml
(35). The authors were not able to detect local recurrence in
patients with PSA values below 0.45 ng/ml with 1.5-T MRI.
in vivo 32: 125-131 (2018)
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Figure 2. Comparison of prostate-specific antigen (PSA) levels in
patients whose tumor could not be detected by magnetic resonance
imaging versus patients who had tumors that was detected. The bottom
and top of each box represent the first and third quartiles, respectively.
The band shows the median of each group. Outliers were defined as
values beyond the 1.5-fold interquartile range (bars) and are marked
with an asterisk. The difference between groups was calculated using
the Mann-Whitney U-test. 
These results concur with those provided by Silverman and
coworkers, who reported the range where recurrent disease was
suspected to be 0.4-11 ng/ml (38). Three studies reported that
detection of local failure may be possible in patients with a PSA
level below 0.4 ng/ml but one study was performed under
systemic treatment for prostate cancer (37), therefore the results
do not apply to the typical situation in which salvage radiation
therapy is initiated. Rischke et al. were able to detect suspicious
lesions in 66% of patients with a median PSA level of 0.51
ng/ml (range=0.11-2.38 ng/ml; 1.5-T MRI) (36). Another small
series was reported by Roy et al., who estimated a sensitivity
of 97% using T2-weighted MRI plus DCE-MRI (mean
PSA=0.98 ng/ml, range=0.3-2.8 ng/ml) (47). Taken together,
evidence on early detection of recurrence after radical
prostatectomy at a PSA level below 0.5 ng/ml is inconsistent.
Our data are in line with the studies performed with 1.5-T MRI,
indicating that improvements by 3-T MRI are not sufficient for
an earlier detection of local recurrence. Additionally, our data
showed an association between PSA level and PF, but not with
MTT. These observations must be confirmed in larger series. It
has been shown that PF is a marker for angiogenesis (48);
however, larger studies are needed to show if its quantification
has a clinical or prognostic significance. 
The weakness of this study is its small sample size.
Additionally, as in most other studies on this issue, local
recurrence was not confirmed by biopsy, only by treatment
outcome (in terms of PSA response). It was not possible to
improve detection cut-off compared to the best reported results
using 1.5-T MRI with our approach. Reported studies on the
subject are not yet sufficient to estimate the sensitivity and
specificity in patients with a PSA level below 0.5 ng/ml.
Potentially, the ongoing MRI-Mapped Dose-Escalated Salvage
Radiotherapy Post-Prostatectomy-trial (49) will provide further
insight. Furthermore, contrast agents such as superparamagnetic
iron oxides (50) may lower detection limits in future studies. 
Conclusion
Detection of gross recurrence by MRI of the prostatic fossa
might improve tumor control if radiation doses could be
escalated without compromising side-effect profiles. Our data
indicate that high field strength alone is not sufficient to reliably
detect recurrence in the prostatic fossa at PSA values below 0.5
ng/ml. This is in line with most published studies reporting on
1.5-T MRI application and indicates an unmet need for better
imaging of the prostatic fossa after radical prostatectomy. 
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